- Open Access
- Open Peer Review
TaxKB: a knowledge base for new taxane-related drug discovery
© Murugan et al. 2015
- Received: 3 December 2014
- Accepted: 19 June 2015
- Published: 28 June 2015
Taxanes are naturally occurring compounds which belong to a powerful group of chemotherapeutic drugs with anticancer properties. Their current use, clinical efficacy, and unique mechanism of action indicate their potentiality for cancer drug discovery and development thereby promising to reduce the high economy associated with cancer worldwide. Extensive research has been carried out on taxanes with the aim to combat issues of drug resistance, side effects, limited natural supply, and also to increase the therapeutic index of these molecules. These efforts have led to the isolation of many naturally occurring compounds belonging to this family (more than 350 different kinds), and the synthesis of semisynthetic analogs of the naturally existing molecules (>500), and has also led to the characterization of many (>1000) of them. A web-based database system on clinically exploitable taxanes, providing a link between the structure and the pharmacological property of these molecules could help to reduce the druggability gap for these molecules.
Taxane knowledge base (TaxKB, http://bioinfo.au-kbc.org.in/taxane/Taxkb/), is an online multi-tier relational database that currently holds data on 42 parameters of 250 natural and 503 semisynthetic analogs of taxanes. This database provides researchers with much-needed information necessary for drug development. TaxKB enables the user to search data on the structure, drug-likeness, and physicochemical properties of both natural and synthetic taxanes with a “General Search” option in addition to a “Parameter Specific Search.” It displays 2D structure and allows the user to download the 3D structure (a PDB file) of taxanes that can be viewed with any molecular visualization tool. The ultimate aim of TaxKB is to provide information on Absorption, Distribution, Metabolism, and Excretion/Toxicity (ADME/T) as well as data on bioavailability and target interaction properties of candidate anticancer taxanes, ahead of expensive clinical trials.
This first web-based single-information portal will play a central role and help researchers to move forward in taxane-based cancer drug research.
- Anticancer drugs
- Drug discovery
- Semisynthetic taxanes
Worldwide, cancer is a major public health issue accounting for approximately 8.2 million deaths and approximately 14 million new cases in 2012 that is expected to rise to 22 million annually within the next 20 years [http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx]. Globally vast amount of resources are being invested for the prevention, diagnosis, and treatment of cancer. Natural compounds have often offered new leads for novel molecular structures with anticancer activity whose synthesized analogs showed improved efficacy and toxicity profiles . The chemical diversity of these compounds has long been explored as a rich source for the identification of unique scaffold of structures that led to many natural product-based drugs in the market. A recent review reports that in 49 % of all cancer drugs, it was either the natural product or its derivative that served as a starting point for the rational drug design process . Among the recently discovered chemotherapeutic drugs, taxanes are considered to be the most powerful group of compounds . Moreover, some of the promising results from clinical studies have led various oncologists, researchers, and drug manufacturers to anticipate their future consideration and development in the field of cancer .
National Cancer Institute discovered the first taxoid in 1960s. Schiff and his coworkers revealed the unique pharmacological mechanisms of taxanes during 1979. These taxanes bind to the microtubules, stabilize them, and prevent their depolymerization thereby inhibiting cell growth . Furthermore, mechanisms of their molecular action are well characterized and include (i) cell division control 2 (cdc-2) kinase activation, (ii) cyclin B-1 stabilization, (iii) spindle assembly checkpoint activation, (iv) apoptosis induction through B-cell lymphoma 2 (bcl-2) phosphorylation, and (v) inhibition of cell proliferation . The natural diterpene taxane, Paclitaxel and the semisynthetic taxane, Docetaxel are deemed to be the most important among the anticancer drugs. Their discovery was a breakthrough which is now considered a major milestone in natural product-based anticancer drug discovery and development . There are several key reasons why taxanes are of importance in cancer drug discovery. These include their clinical efficacy, potential for modification and improvement, unique mechanism of action on tubulin polymerization rather than the DNA, suitability for combination therapy along with novel mitotic target agents being developed, as well as selective antivascular action at nontoxic doses . Furthermore, the development of novel taxane derivatives with enhanced anticancer activity, fewer and milder side effects, and superior pharmacological properties would not only maximize the induced benefits but also will reduce the high economic and human costs worldwide .
Unfortunately, these agents suffer from issues such as drug resistance, lack of specificity, toxicity, poor solubility, and limited natural occurrence and availability. The issue of drug resistance leads to a lack of response and eventual relapse of the disease in many patients. Moreover, limited solvent availability for these compounds restricts dose escalation and increases their toxicity which necessitates the use of premedications . They are not cell-specific and do not show similar results on the microtubules when used at different concentrations (they cause microtubule arrangement into bundles at higher concentrations while suppressing and stabilizing microtubule dynamics without altering the polymer mass at lower concentrations) . Therefore, therapeutic index, defined as the ratio of the TD50 (or LD50) to the ED50 as determined from quantal dose–response curves  which indicates the safety profile of taxanes, needs to be improved either by developing new drugs that target microtubules at different sites, or by improving drug scheduling or formulations or by increasing drug specificity to increase antitumor activity and decrease its toxicity . Despite some of these disadvantages, the utility of these compounds in cancer cannot be disregarded, given their advantages . For example, it has been found that a suitable modification of toxoids at the C10 site and replacement of phenyl group at C3 position with an alkenyl or alkyl group leads to second-generation toxoids with one to two orders of magnitude more potency against drug-resistant cancer cell lines . Moreover, the scarcity of taxanes from natural sources also impedes their further development. Currently, commercial demands are met through alternate semisynthetic processing of their more abundant precursors. For example, Docetaxel is derived from 10-deacetylbacatin III, a precursor found in more abundant Taxus (yew) species . Analogs of existing drugs have also been synthesized to increase drug targeting, pharmacokinetic profile, and drug supply . To overcome the aforementioned clinical problems, the structure of taxanes has been extensively modified to obtain new molecules with a better therapeutic index and the ability to overcome drug resistance . The enormous scope of taxanes encouraged extensive and intensive research which led to the isolation of 350 natural taxanes from yews, synthesis of more than 500 semisynthetic analogs, and characterization of thousands of taxane molecules. The sheer volume of these discoveries motivates the need for a web-based database system to help cancer drug developers in the war against cancer.
Although a number of databases on chemically active natural compounds have been published , there is no database devoted to the taxane family of compounds, despite their success as antitumor agents. Examples of these existing databases on natural compounds other than taxanes include SuperNatural , CancerResource , and NPACT . Hence, a comprehensive web-based database of taxanes linking their chemical structures with known pharmacological properties is a much-needed tool in cancer drug development. Such a tool will improve our understanding of these compounds by allowing easy screening of clinically exploitable taxanes, serving quantitative structure–activity relationships, and helping to optimize the initial lead compounds from them. These improvements promise economic as well as scientific gains for the pharmaceutical industry, thus enabling the creation of this platform.
The current new cancer therapy development approaches are difficult, costly, and time-consuming, potentially taking >10 years to develop a new drug and frequently costs more than 1 billion US dollars. In addition, the level of attrition is very high with about 80–95 % of new drugs failing in the course of clinical trials due to lack of efficacy or unacceptable toxicity . Hence, the ultimate aim of the present TaxKB database was to provide candidate anticancer drug taxanes’ ADME/T (Absorption, Distribution, Metabolism, and Excretion/Toxicity) information ahead of expensive clinical trials for predicting their bioavailability and target interacting properties. If the taxane or its fragments follows the Lipinski’s Rule of five (low molecular weight ≥500, H bond donor ≥5, H bond acceptors ≥10, log P ≥ 5) then the TaxKB information will allow for their optimization into leads .
The following pieces of information were retrieved from this database suggesting its usefulness for taxane-based cancer drug research and for mining the most appropriate taxane for clinical development. (i) Taxanes have a minimum molecular weight of 200 Da and the percentage of taxanes weighing between 600 and 800 Da is about 45 %. (ii) All taxanes have a similar composition with carbon present at the highest percentage of about 70 %, oxygen at an average of 20 %, and hydrogen at about 10 %, while in some compounds nitrogen is also present at low numbers (e.g. 10-Deacetyltaxine I, 10-Dideacetyltaxine II, and 9-Deacetyltaxine I). (iii) Overall, 50 % of all taxanes’ monoisotopic mass values are in the range of 600–800. (iv) About 32 % of taxanes have a molar volume that lies in the range of 500–600 Da, within that range, 31 % weigh between 400 and 500 Da. Information such as these provided by the database, will be highly useful for selecting the best taxanes as drug candidates.
The presented web-based TaxKB database is a new resource available for cancer drug developers that would enable easy screening of clinically exploitable taxanes and allow the generation of fragment and scaffold containing libraries and designing of novel taxane leads with properties similar to the original compounds. Key features of the database include the physicochemical and drug-likeness property data of taxanes of both natural and synthetic origin.
TaxKB is a single-information portal for the most successful blockbuster natural drug compound ever discovered, namely, taxane. To our knowledge, it is the first and only web-based resource integrating multidisciplinary data on taxanes as derived from different drug development efforts so far. It provides a link between two independent processes, taxane-based cancer drug development, and the ADME/T and thus provides a better understanding and earlier detection of potential development failures. Hence, it serves as an excellent online resource for taxane-related drug discovery. The motto of today’s drug discovery and development industry is “Fail faster, Fail cheaper.” As a result, scientists are constantly striving for new ways to eliminate poor drug candidates earlier in the drug discovery cycle. The rapid pace of development of new and advanced taxane analogs can enhance the overall quality of drugs and therefore health care. TaxKB, as an information resource for taxanes, their analogs, and their properties can assist researchers in developing new drug candidates based on the various properties of these molecules. Several enhancements will be carried out in the upcoming release, including incorporation of additional taxane structures as well as more properties of these molecules, as new dimensions that can further improve the present pace of new taxane drug discovery.
This project was supported by King Saud University, Deanship of Scientific Research, College of Science Research center.
- Narang AS, Desai DS. Anticancer drug development. Unique aspects of pharmaceutical development. In: Lu Y, Mahato RI, editors. Pharmaceutical perspectives of cancer therapeutics. Springer, LLC; 2009.Google Scholar
- Mangal M, Sagar P, Singh H, Raghava GPS, Agarwal SM. NPACT: naturally occurring plant-based anti-cancer compound-activity-target database. Nucleic Acids Res. 2013;41:D1124–9.View ArticlePubMedGoogle Scholar
- Verma RP, Hansch C. QSAR modeling of taxane analogues against colon cancer. Eur J Med Chem. 2010;45:1470–7.View ArticlePubMedGoogle Scholar
- Fauzee NJS, Dong Z, Wang YI. Taxanes: promising anti-cancer drugs. Asian Pac J Cancer Prev. 2011;12:837–51.PubMedGoogle Scholar
- Feng L, Mumper RJ. A critical review of lipid-based nanoparticles for taxane delivery. Cancer Lett. 2013;334:157–75.View ArticlePubMedGoogle Scholar
- Murray S, Briasoulis B, Linardou H, Bafaloukos D, Papadimitriou C. Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat Rev. 2012;38:890–903.View ArticlePubMedGoogle Scholar
- Song L, Chen QH, She XE, Chen XG, Wang FP. Conversional synthesis and cytotoxic evaluation of novel taxoid analogs. J Asian Nat Prod Res. 2011;13(9):787–98.View ArticlePubMedGoogle Scholar
- Broxterman HJ, Georgopapadakou NH. Anticancer therapeutics: “Addictive” targets, multi-targeted drugs, new drug combinations. Drug Resist Updat. 2005;8:183–97.View ArticlePubMedGoogle Scholar
- von Minckwitz G, Martin M, Wilson G, Alba E, Schmidt M, Biganzoli L, et al. Optimizing taxane use in MBC in the emerging era of targeted chemotherapy. Crit Rev Oncol Hematol. 2013;85:315–31.View ArticleGoogle Scholar
- Trevor AJ, Katzung BG, Kruidering-Hall M, Masters SB. Pharmacodynamics. In: Katzung and Trevor’s Pharmacology Examination & Board Review. 10th edition; McGraw Hill; 2013, p. 17.Google Scholar
- Du H, Zhang M, Yin D, Li Y, Chen X. Synthesis and biological evaluation of new 4‐Deacety‐1,7,9‐trideoxy‐10‐oxopaclitaxel via sinenxan A. Synth Commun. 2007;37(21):3779–91.View ArticleGoogle Scholar
- Zelnak AB. Clinical pharmacology and use of microtubule-targeting agents in cancer therapy. In: Jun Z, editor. Methods in molecular medicine, microtubule protocols, vol. 137. Totowa NJ: Humana Press Inc; 2007. p. 209–34.View ArticleGoogle Scholar
- Hu J, You F, Yang S, Li Y. Quantitative determination of Lx2-32c, a novel taxane derivative, in rat plasma by liquid chromatography–tandem mass spectrometry. J Pharm Biomed Anal. 2014;88:483–8.View ArticlePubMedGoogle Scholar
- Dunkel M, Fullbeck M, Neumann S, Preissner R. SuperNatural: a searchable database of available natural compounds. Nucleic Acids Res. 2006;34:D678–83.View ArticlePubMedGoogle Scholar
- Ahmed J, Meinel T, Dunkel M, Murgueitio MS, Adams R, Blasse C, Eckert A, Preissner S, Preissner R. CancerResource: a comprehensive database of cancer-relevant proteins and compound interactions supported by experimental knowledge. Nucleic Acids Res. 2010; 1–8. doi:10.1093/nar/gkq910
- Itokawa H, Lee KH. Taxus: the genus Taxus. London: Taylor & Francis; 2003. p. 27.Google Scholar
- Johnson Jr, JH. Chemistry of taxanes and Taxus species. Ph.D Thesis. University of Florida; 1998Google Scholar
- Vobořilováa J, Němcováa V, Neubauerováa J, Ojimab I, Zanardib I, Gutc I, et al. Cell death induced by novel fluorinated taxanes in drug-sensitive and drug-resistant cancer cells. Invest New Drugs. 2011;29(3):411–23.View ArticleGoogle Scholar
- Dai JG, Guo HZ, Ye M, Zhu WH, Zhang DY, Hu Q, et al. Biotransformation of 4(20),11-taxadienes by cell suspension cultures of Platycodon grandiflorum. J Asian Nat Prod Res. 2003;5(1):5–10.View ArticlePubMedGoogle Scholar
- Wang L, Bai L, Tokunaga D, Watanabe Y, Hasegawa T, Sakai JI, et al. The polar neutral and basic taxoids isolated from needles and twigs of Taxus cuspidata and their biological activity. J Wood Sci. 2008;54:390–401.View ArticleGoogle Scholar
- Xie D, Jia HT, Zhang Y, Zou JH, Yin DL, Chen XG, et al. Four new minor taxanes from cell cultures of Taxus chinensis. J Asian Nat Prod Res. 2009;11(6):490–7.View ArticlePubMedGoogle Scholar
- Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41:D955–61.View ArticlePubMedGoogle Scholar
- Gimenez BG, Santos MS, Ferrarini M, Fernandes JP. Evaluation of blockbuster drugs under the rule-of-five. Pharmazie. 2010;65(2):148–52.PubMedGoogle Scholar
- Miteva MA, Violas S, Montes M, Gomez D, Tuffery P, Villoutreix BO. FAF-Drugs: free ADME/tox filtering of compound collections. Nucleic Acids Res. 2006;34:W738–44.View ArticlePubMedPubMed CentralGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.